NEW YORK, NY / ACCESSWIRE / August 31, 2020 / Focus Financial Partners Inc. (NASDAQ:FOCS) ("Focus"), a leading partnership of independent, fiduciary wealth management firms, announced today that Seasons of Advice Wealth Management, LLC ("Seasons of Advice"), an integrated wealth management firm headquartered in New York City, has entered into an agreement to join the Focus partnership. The transaction is expected to close in the fourth quarter of 2020, subject to customary closing conditions.

Seasons of Advice was founded by Charles Hamowy, Christopher Conigliaro and Matthew Woolf in 2017. Seasons of Advice employs a full-service model that offers financial planning, investment management and insurance-related services to high net worth clients primarily in the New York City area.

Seasons of Advice views environmental, social and governance ("ESG") investing as a critical element of its investment management process, and has developed its proprietary Stewardship Personal Values PortfoliosSM to help clients meet their financial goals responsibly. These portfolios represent a significant potential growth opportunity for the firm across all client segments, especially younger and wealthier clients.

"We started Seasons of Advice to build a financial planning firm based on an innovative investment and planning approach that we believed would result in superior outcomes for our clients," said Charles Hamowy, CEO of Seasons of Advice. "ESG investing has also been an important part of our approach, as we view ESG as a critical component of the growth of our industry, and believe that investors can ‘do well by doing good' by seeking attractive returns by investing in companies that are sustainable and responsible from an ESG perspective. We expect that the resources that Focus offers will enable us to build the necessary scale to accelerate our growth and expand our ESG offerings, while also maintaining our core tenets of independence and highly personalized client service. We look forward to our partnership with Focus as we build Seasons of Advice well into the future."

"We are very pleased to welcome Seasons of Advice to the Focus partnership," said Rudy Adolf, Founder, CEO and Chairman. "This young firm will expand our presence in the important New York City wealth management market, and is led by an innovative management team with a strong and diverse group of next generation leaders. They have built an enviable track record of growth and client service that will position Seasons of Advice to capitalize on the substantial forward growth opportunity.

This transaction is another example of how Focus' unique value proposition of entrepreneurship, access to value-added services and permanent capital is resonating in the marketplace. We are a leader in a highly attractive industry that has historically experienced strong growth following market downturns. The resiliency and stability of our business positions us particularly well to capitalize on that trend."

About Focus Financial Partners

Focus Financial Partners Inc. is a leading partnership of independent, fiduciary wealth management firms. Focus provides access to best practices, resources and continuity planning for its partner firms who serve individuals, families, employers and institutions with comprehensive wealth management services. Focus partner firms maintain their operational independence, while they benefit from the synergies, scale, economics and best practices offered by Focus to achieve their business objectives. For more information about Focus, please visit focusfinancialpartners.com.

About Seasons of Advice Wealth Management

Founded in 2017, Seasons of Advice Wealth Management, LLC offers integrated wealth management services to individuals and their families across the United States. The firm's comprehensive service offering includes financial planning, investment management, insurance services and ESG investing. Seasons of Advice's team of specialists works with clients through a collaborative and seasonal approach to address clients' needs holistically and comprehensively. For more information about Seasons of Advice, please visit www.soawealth.com.

Cautionary Statement Concerning Forward-Looking Statements

This release contains certain forward-looking statements that reflect Focus' current views with respect to certain current and future events. These forward-looking statements are and will be, subject to many risks, uncertainties and factors relating to Focus' operations and business environment, including, without limitation, uncertainty surrounding the current COVID-19 pandemic, which may cause future events to be materially different from these forward-looking statements or anything implied therein. Any forward-looking statements in this release are based upon information available to Focus on the date of this release. Focus does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any statements expressed or implied therein will not be realized. Additional information on risk factors that could affect Focus may be found in Focus' filings with the Securities and Exchange Commission.

Investor and Media Contact

Tina Madon
Senior Vice President
Head of Investor Relations & Corporate Communications
Focus Financial Partners
P: +1-646-813-2909
tmadon@focuspartners.com

SOURCE: Focus Financial Partners Inc.

ReleaseID: 604011

CLEARWATER, FL / ACCESSWIRE / August 31, 2020 / Endurance Exploration Group, Inc., (OTC PINK:EXPL) ("Endurance" or the "Company"), a company specializing in shipwreck research, survey and recovery, is pleased to announce that it has entered into a contract extension with an Island Nation ("Nation") located in the Indian Ocean, granting EXPL exclusive rights to certain shipwreck exploration and recovery activities in the Nation's territorial waters. The contract extension grants rights for a period of three years, ending on August 28, 2023. The contract extension preserves the economic terms of the original agreement, whereby, Endurance will receive 75% the net profits, after deducting all search, recovery and other costs, realized from any commercial monetization of recovered cargoes, and the Nation will receive 25%.

The Nation was formed at the crossroads of different civilizations; and has been highly influenced over the centuries by African, Arabic, and modern Western cultures. There are numerous known Western shipwrecks located in the Nation's territorial waters dating from as early as 1510, and speculatively, additional unknown Arabic and, potentially, Chinese trading ships from earlier periods may have been lost. Some of the known, but undiscovered and not yet salvaged, Western shipwrecks include (names abbreviated) : "SR", Portuguese, 1510; "AW", Portuguese, 1616; "SJ", Portuguese 1616, "S", English (EIC), 1635; "PH", English East India-man, 1690; "R", EIC, 1699, "H", EIC, 1774; and "B", EIC, 1782. Some of the wrecks were carrying large documented cargoes of precious metals specie and bullion, destined to be exchanged for exotic goods in the East Indies.

While Endurance originally received permissions from the Nation a number of years ago, our deep water search and recovery capabilities, including the purchase of a Bluefin/General Dynamics Autonomous Underwater Vehicle, have only recently been expanded to allow us to explore the deeper waters surrounding this Island Nation which are suspected of holding these valuable wreck sites.

About Endurance Exploration Group, Inc.:
Endurance Exploration Group, Inc. specializes in historic shipwreck research, subsea search, survey and recovery of lost ship containing valuable cargoes. Over the last 10 years, Endurance has developed a research database of over 1,400 ships that are known to be lost with valuable cargoes in the world oceans, and in 2013 began subsea search and survey operations.

www.eexpl.com
www.facebook.com/EnduranceExplorationGroup

Forward Looking Statements:

Cautionary Information Regarding Forward-Looking Statements.

This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties including but not limited to legal and operational risks of offshore, historic shipwreck recovery.

Forward-looking statements contained in this press release are made under the Safe Harbor Provision of the Private Securities Litigation Reform Act of 1995. Any such statements are subject to risks and uncertainties that could cause actual results to differ materially from the anticipated. The information contained in this release is as of May 8, 2017. Endurance Exploration Group, Inc. assumes no obligation to update forward-looking statements contained in this press release as the result of new information or future events or developments.

Contact Information:
Media Contacts:
Micah J. Eldred
CEO
727-502-0508

SOURCE: Endurance Exploration Group, Inc.

ReleaseID: 603947

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / Capricor Therapeutics ("Capricor") (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, today announced that it will be presenting at the LD 500 investor conference on Friday, September 4 at 9:20 AM ET / 6:20 AM PT. Linda Marbán, Ph.D, Chief Executive Officer, will be presenting to a live virtual audience.

Webcast link: https://www.webcaster4.com/Webcast/Page/2019/36933

Register for the conference here: https://ld500.ldmicro.com/.

"We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space." stated Chris Lahiji, Founder of LD.

The LD 500 will take place on September 1st through the 4th.

View Capricor's profile here: http://www.ldmicro.com/profile/CAPR.

Profiles powered by LD Micro – News Compliments of Accesswire

About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and COVID-19. Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. We are now developing two potential vaccines for COVID-19 as part of our exosome platform. For more information, visit www.capricor.com and follow the Company on Facebook, Instagram and Twitter.

About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.

What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.

The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on March 27, 2020 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 as filed with the Securities and Exchange Commission on August 10, 2020. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor's exosome-based candidates have been approved for clinical investigation.

For more information, please contact:

Media Contact:
Caitlin Kasunich
KCSA Strategic Communications
ckasunich@kcsa.com
212.896.1241

Investor Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
617.435.6602

Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
310.358.3201

SOURCE: Capricor Therapeutics via LD Micro

ReleaseID: 603948

VIENNA, VA / ACCESSWIRE / August 31, 2020 / CEL-SCI Corporation (NYSE American:CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the LD 500 investor conference on Wednesday, September 2nd at 10:20 a.m. ET. Geert Kersten, Chief Executive Officer of CEL-SCI, will be presenting to a live virtual audience.

A live audio webcast of the chat will be available at https://www.webcaster4.com/Webcast/Page/2019/36149 or on the Investor Relations section of CEL-SCI's website at cel-sci.com/new-investor-information/, where it will be archived for approximately 90 days.

View CEL-SCI's profile here: http://www.ldmicro.com/profile/CVM

About CEL-SCI Corporation

CEL-SCI believes that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in the Phase 3 study CEL-SCI treated patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck with the investigational product Multikine* first, BEFORE they received surgery, radiation and/or chemotherapy. This approach is unique. Most other cancer immunotherapies are administered only after conventional therapies have been tried and/or failed. Multikine (Leukocyte Interleukin, Injection), has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.

CEL-SCI believes that this Phase 3 study is the largest Phase 3 study in the world for the treatment of head and neck cancer. Per the study's protocol, newly diagnosed patients with advanced primary squamous cell carcinoma of the head and neck were treated with the Multikine treatment regimen first – for 3 weeks prior to receiving the Standard of Care (SOC), which involves surgery, radiation or concurrent radiochemotherapy. Multikine is designed to help the immune system "see" the tumor at a time when the immune system is still relatively intact and thereby thought to better be able to mount an attack on the tumor. The aim of treatment with Multikine is to boost the body's immune system prior to SOC to attack the cancer. The Phase 3 study is fully enrolled with 928 patients and the last patient was treated in September 2016. To prove an overall survival benefit, the study requires CEL-SCI to wait until 298 events have occurred among the two main comparator groups. This study milestone occurred in late April 2020. The study is currently in the database lock and analysis phase.

The Company's LEAPS technology is being developed for rheumatoid arthritis and as a potential treatment of COVID-19 in hospitalized and at-high-risk patients. The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.

About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.

What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.

The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to Multikine and the Phase 3 clinical trial of Multikine in patients with advanced primary squamous cell carcinoma of the head and neck. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical trials or nonclinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K/A for the year ended September 30, 2019. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine. Further research is required, and early-phase clinical trial results must be confirmed in the Phase 3 clinical trial of this investigational therapy that is in progress.

COMPANY CONTACT
Gavin de Windt
CEL-SCI Corporation
(703) 506-9460

SOURCE: CEL-SCI Corporation 

ReleaseID: 603869

New resource model increases confidence and better defines leachable material for Bankable Feasibility Study

VANCOUVER, BC / ACCESSWIRE / August 31, 2020 / Golden Predator Mining Corp. (TSX.V:GPY)(OTCQX:NTGSF) (the "Company") today released the results of a NI 43-101-compliant Mineral Resource Estimate for its licensed 100%-owned Brewery Creek mine project ‎located approximately 55 km by road from Dawson City, Yukon(1). A supporting NI 43-101 Technical Report will be filed on SEDAR at www.sedar.com within 45 ‎days of this release.‎

As of August 26, 2020, Gustavson & Associates LLC. estimates an Indicated leachable resource of 22,200,000 tonnes at 1.11 g/t gold containing 789,000 ounces, plus an Inferred leachable resource of 16,800,000 tonnes at 0.92 g/t gold containing 497,000 ounces. The estimate utilizes an average cutoff grade of 0.37 g/t gold at a gold price of $1,500/oz USD within a pit shell calculated at $2,000/oz USD. The report also estimates an additional 30,600,000 tonnes of Inferred sulphide resource at 0.84 g/t gold containing 828,000 ounces. The updated estimate does not include material on the heap leach pad which will be reported separately within the Restart Study being prepared by Kappes, Cassiday, LLC.

The 2020 Mineral Resource Estimate highlights include:

The Mineral Resource Estimate incorporates a metallogenic leach recovery model applied to each 3m by 3m block based on assay data, bottle roll and column leach test work to better define leach-recoverable gold mineralization and to provide a more detailed and defined methodology for mine modeling. The updated estimate reports an increase of leachable Indicated, Inferred and Inferred sulphide gold resources over the previous report, and the current model has a much higher confidence level pertaining to leachable material than the 2019 estimate. The updated model incorporates a more detailed and accurate analysis that will make a critical contribution to the development of mine plans in the Bankable Feasibility Study (BFS);

The current mineral resource estimate and model confirms that the 2019 drill program successfully connected and combined the Fosters, Canadian, Kokanee and Golden deposits into one large, elongated pit shell extending approximately 3.5km in length, renamed the "Keg" pit shell and resource;
As a priority, Gustavson recommends a drill program to in-fill high potential areas to add additional leachable resources in time for inclusion in the BFS. Drilling in 2019 indicated that the 400m gap between Keg and the Lucky deposit is well mineralized and oxidized and requires increased drill density to calculate a resource incorporating the gap and the Lucky deposit into the greater Keg pit shell;
Gustavson was able to model the Bohemain and Schooner resource areas into a larger single pit shell;
Gustavson analysis suggests that the planned 2020 metallurgical drilling will further define the limits of the leachable material potentially adding additional material to the leachable category;
The new 2020 leach recovery model clarifies issues identified with the Moosehead deposit which had previously caused the Company to remove Moosehead from its list of licensed resources areas. In the new estimate, Moosehead contains 1.2 Mt of 0.91 g/t leachable gold for 35,000 ounces Indicated and an additional 0.6 Mt of 0.83 g/t gold for 16,100 ounces of Inferred Resources;
Identification of a maiden resource of 700,000 tonnes of 0.65 g/t gold containing 13,000 ounces of leachable near surface gold at the Camp Zone, immediately north of and adjacent to the leach pad area. The Camp Zone remains open to expansion along strike.

Brewery Creek maps and a 3D video of resource areas can be viewed at: https://youtu.be/UEqsNt9CcLU and http://www.goldenpredator.com/_resources/news/BC-Property-Maps-2020.pdf

"The updated Mineral Resource Estimate better establishes leachability on a block by block basis for inclusion in the ongoing Feasibility Study. We can now proceed with confidence to prepare detailed mine plans based on leachable material. We are optimistic that we can add further leachable resources in the near term from the drilling that will begin next month," said Janet Lee-Sheriff, Chief Executive Officer. "Additionally, Gustavson's confirmation of the combined larger pits should mean improved mining efficiencies and reduced operating costs which will be reflected in the upcoming Feasibility Study."

2020 Drill Program

Golden Predator also announces it will commence an approximate 3,000m of reverse circulation drilling in September 2020, in addition to a 1,000m metallurgical PQ core program, to ensure the priority recommendations from the Gustavson Report are completed and incorporated into the Bankable Feasibility Study. The drill program includes:

Drilling in the ~400m gap between the Lucky resource area and the Keg pit to build on the 2019 drilling which indicates the mineralization is continuous between the two deposits. Additional drilling will be focused on increasing the drill density with the goal of incorporating the Lucky resource into the Keg pit. The Mineral Resource Estimate Report recommends additional infill drilling in this area as a priority item to expand the eastern margin of the Keg pit another 1,000 m along strike to encompass both the gap area and the Lucky resource area;

Drilling in the Classic area, which is the single largest exploration target on the project, where younger gold mineralization occurs disseminated and in stockworks in a syenite intrusive covering a large area in the southern part of the property. Surface mineralization was identified in 2019 approximately 1km southeast from the open- ended resources at both Classic and Lone Star. This promising large target is outside the scope of the Feasibility Study but provides significant exploration potential for expanding the project.

Brewery Creek Mine: Resources1

2020 Brewery Creek Mineral Resource Estimate(1)

Leachable

Tonnes

g/t

Gold Oz.

Indicated

22,200,000

1.11

789,000

Inferred

16,800,000

0.92

497,000

Sulphide

Tonnes

g/t

Gold Oz.

Inferred

30,600,000

0.84

828,000

Materials on the heap leach pad were not included in the resource update.

Mineral Resources estimates conducted within a pit shell developed at $2000/oz gold with an internal cut-off grade calculated at $1500/oz gold was used to report mineral resource inventories

The resource estimate is based on a recovery model created from assay data, bottle and column leach test work and historic recovery analysis instead of a less accurate visual oxide-sulfide boundary developed from geologist drill logs. Sedimentary and intrusive rocks, which have distinct metallurgical characteristics, were estimated separately based on gold-grade distribution analysis.

The current 2020 Mineral Resources Estimate supersedes the 2019 Mineral Resource Estimate. A supporting NI 43-101 Technical Report will be filed on SEDAR at www.sedar.com within 45 ‎days of this release.‎ The Company intends to host a conference call with a Q&A session upon public filing of the Report.

Brewery Creek Work Program

Work is underway to develop an updated multi-year mine plan for the advancement of the Brewery Creek project. The first component focuses on the potential reprocessing of the approximately 9.5 million tonnes of material remaining on the heap leach pad to provide production revenue in the early stages of a restart while also providing a sound environmental foundation for future phases and the eventual closure of the mine. The second component is focused on completing the original Viceroy mining plan as currently assessed and licensed. The third component is an expansion beyond the current license which would extend the mine plan and require additional licensing; planning is underway.

The Heap Leach Reprocessing Study is being conducted by Kappes Cassiday & Associates of Reno, Nevada, ("Kappes") to determine the feasibility of reprocessing the approximately 9.5 million tonnes of run of mine material left by the previous operator on the project's heap leach pad to extract additional gold. The study includes an inventory of the mineralized material remaining on the heap followed by detailed analysis of all the key parameters involved in reconstructing or adding necessary infrastructure including a crushing plant, the Adsorption-Desorption-Recovery ("ADR") plant and assay lab. The study now is 90 % complete. The study will include a project implementation schedule, sourcing, and economic cash flow model sufficiently detailed to move directly into procurement, development and construction if economically warranted.

Due to the positive progress realized during the work to restart the Brewery Creek Mine from reprocessing of existing heap leach material, the Company has decided to accelerate work on the Hard Rock Mining and Feasibility Study plan to be completed by Tetra tech, Inc of Golden, Colorado ("Tetra Tech"). The study will include feasibility level mine planning for the resumption of the mining of material from leachable resources contained within the licensed area and reported in the Company's Mineral Resource Estimate.

The results of all studies will integrate into a single comprehensive Feasibility Study for the Company's Brewery Creek gold project in Canada's Yukon to be completed by Kappes Cassiday. This definitive comprehensive Bankable Feasibility Study is expected to be complete by year-end 2020. Any production decisions would be dependent on the outcome of a study demonstrating positive technical and economic viability.

Brewery Creek Mine: Production History

The Brewery Creek Mine is a licensed brownfields heap leach gold mine that was operated by Viceroy Minerals Corporation from 1996 to 2002. Brewery Creek is authorized to restart mining activities as defined within the Quartz Mining License and Water License. The Company intends to resume mining and processing of licensed deposits when supported by an independent study that outlines technical and economic viability. The 180 km2 property is located 55 km east of Dawson City and is accessible year-round by paved and improved gravel roads. Significant infrastructure remains in place, allowing for a timely restart schedule under existing licenses.

The technical content of this news release has been reviewed and approved by Michael Maslowski, CPG, a Qualified Person as defined by National Instrument 43-101 and is employed by the Company as its Chief Operating Officer.

About Golden Predator Mining Corp.

Golden Predator is advancing the past-producing Brewery Creek Mine towards a timely resumption of mining activities, under its Quartz Mining and Water Licenses, in Canada's Yukon. With established resources grading over 1.0 g/t Gold and a Bankable Feasibility Study considering the restart of heap leach operations at the Brewery Creek Mine underway, 2020 proves to be a pivotal year for the Company.

For additional information:
Janet Lee-Sheriff
Chief Executive Officer
(604) 260-8435
info@goldenpredator.com
www.goldenpredator.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This press release contains forward-looking information that involve various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations that the Brewery Creek will advance to an early production decision, or the extent of any additional mineral resource that could result from incorporating 2019 exploration drilling. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company assumes no obligation to update forward-looking information should circumstances or management's estimates or opinions change.

The 2020 Mineral Resource Estimate was conducted in accordance with CIM guidelines and is reported in a NI 43-101 Technical Report which will be filed on SEDAR and the Company's website within 45 days.

SOURCE: Golden Predator Mining Corp.

ReleaseID: 604043

Assets of $19 million1 purchased free and clear of legacy liabilities for $16 million

Estimated 2021 EBITDA of $7 million to $9 million

Estimated run rate EBITDA of $12 million to $14 million at full capacity

TORONTO, ON / ACCESSWIRE / August 31, 2020 / Trichome Financial Corp. (the "Company" or "Trichome Financial") (CSE:TFC) is pleased to announce that its wholly-owned subsidiary, Trichome JWC Acquisition Corp. ("TJAC") d/b/a JWC ("JWC"), received licensure from Health Canada and closed the acquisition of substantially all of the assets (the "Assets") of James E. Wagner Cultivation Corporation on August 28, 2020 (the "Acquisition"), free and clear of legacy liabilities. The Acquisition was made in connection with James E. Wagner Cultivation Corporation's consensual restructuring proposal with Trichome Financial under the Companies' Creditors Arrangement Act (the "CCAA") that was previously authorized by the Ontario Superior Court of Justice (Commercial List) on June 2, 2020. The Assets were purchased for total consideration of $16 million by way of set-off of Trichome Financial's pre-filing debt and assumption of its debtor-in-possession ("DIP") financing, and will be used by TJAC to continue to produce premium cannabis offerings under the JWC brand.

"The closing of the Acquisition is a transformational opportunity for Trichome Financial. It comes at what we believe to be an inflection point for the Canadian cannabis industry, with increasing monthly recreational sales due to greater retail store openings intersecting with rationalizing cannabis supply, particularly of premium quality, given industry-wide capital constraints. The financial and operational restructuring of the business over the last five months positions JWC to be amongst a select group of Canadian cannabis businesses that will thrive in the coming years. We estimate that the processes we have implemented will generate between $12 million to $14 million of EBITDA once the business is operating at full capacity," said Michael Ruscetta, CEO of Trichome Financial. "This has been an incredible team effort by many talented individuals working for a common purpose. There are many people to thank for their hard work and commitment to success, but none more so than the dedicated employees of JWC. While there is much more to do, I am confident that our team possesses the right mix of skills, expertise and passion to succeed."

Summary of Assets Acquired

TJAC is fully licensed to operate the acquired Assets. Based in Kitchener, Ontario, the Assets include 114,000 square feet of licensed space in two facilities capable of producing approximately 7,000 kilograms per year of premium cannabis. TJAC, operating the JWC business, is one of a small percentage of licensed producers holding a complete set of Health Canada licenses, enabling it to produce and sell both dried flower products as well as extract products. The Assets are fully built out, require nominal capital expenditures for growth, and have operated without interruption during the CCAA proceedings. Finally, TJAC extended employment agreements to 107 people, the vast majority of whom were previously employed by James E. Wagner Cultivation Corporation. The Assets are estimated to be valued at approximately $19 million on a preliminary basis, subject to audit confirmation.

Preliminary, subject to audit confirmation

Summary of Restructuring

Since April 9, 2020, Trichome Financial has overseen an exhaustive financial and operational restructuring of the JWC business. Howard Steinberg, Chief Restructuring Officer and a director of Trichome Financial, led a team of internal and external resources that has systematically rebuilt every functional aspect of the business in a unified approach with an overriding objective to position JWC for commercial success in the Canadian cannabis industry. The following is a summary of the accomplishments to date:

Management: The senior management team has been replaced and augmented in order to align functional roles with specific expertise. Howard Steinberg has led the organizational design and ushered in a collaborative, analytically driven approach to managing the business. Howard has been appointed the CEO of TJAC.

Balance Sheet: Approximately $19 million of James E. Wagner Cultivation Corporation's third-party liabilities were extinguished as a result of the CCAA proceedings and acquisition by TJAC, resulting in substantial cash interest savings.

Cost Structure: Full-time equivalent staffing has been reduced by approximately 40%, from 185 at its peak to 107 upon closing, resulting in annual cost savings of approximately $3 million. Excess vacant space in the building is currently being offered for sublet, which we expect would result in an additional $1 million per year of expense control if completed. Finally, management is anticipating additional material savings from enhanced expense oversight and efficient purchasing of consumable and capital supplies.

Operations & cultivation: With key hires in operations and cultivation, significant progress has been made scheduling production, reducing cycle times and improving plant health. All of these improvements will result in enhanced labour and facility productivity while ensuring production levels and end market demand are in balance.

Sales & marketing: Putting the customer at the apex of the JWC organization is a key priority under Trichome Financial's ownership. To that end, key investments are being made in internal sales and marketing capabilities, brand rejuvenation, and data analytics to ensure that we are constantly meeting the needs and desires of an ever-shifting marketplace.

Product strategy: As part of TJAC's licensure, JWC's genetics bank has been materially upgraded and will offer customers a wider selection of highly coveted strains. It is expected that some of these new strains will be available on shelves by the end of Q1 2021. Finally, product development that meets the needs of customers is central to the strategy going forward. Many new products are being assessed and tested, including hash, which we anticipate will hit the shelves before the end of 2020.

Financial Outlook

As production continues to ramp through the balance of 2020, Trichome Financial is providing the following financial guidance for TJAC:

FY 2021

Capacity Run Rate

Flower Production

5,700 kgs per year

7,000 kgs per year

Net Revenue

$22 million to $24 million

$30 million to $32 million

EBITDA

$7 million to $9 million

$12 million to $14 million

TJAC Capitalization

Upon closing of the Acquisition, Trichome Financial's pre-filing obligations of $7.6 million were converted into equity of TJAC at $1.00 per share. As of closing, amounts outstanding under the DIP were $8.4 million. Of this amount, $7.0 million is being assumed in the form of a secured note, convertible into shares of TJAC at $1.00 per share. The balance, plus future funding requirements, will be funded by way of a non-participating secured grid promissory note ("Grid Note"). As of August 28, 2020 amounts outstanding under the Grid Note were approximately $2.6 million, while cash on hand at TJAC was approximately $1 million. An option plan for management, employees and directors, representing 30% of the fully diluted equity of TJAC was implemented upon closing. All options have an exercise price of $1.00 per share.

Information regarding the CCAA proceedings

Further details of the CCAA proceedings are available under James E Wagner Cultivation Corporation's profile on the System for Electronic Document Analysis and Retrieval (www.sedar.ca) and are also available, along with additional information respecting the CCAA proceedings, on the website of KSV Kofman Inc., the Court-appointed CCAA monitor (the "Monitor") (https://www.ksvadvisory.com/insolvency-cases/case/james-e-wagner-cultivation-corporation) Readers are urged to consult the full text of all documents available on SEDAR and the Monitor's website for further, more detailed, information.

About Trichome Financial Corp.

Trichome Financial is a specialty finance company focused on providing flexible and creative credit solutions to the global legal cannabis market. Trichome was created to address the lack of credit availability in the large, growing and increasingly complex cannabis market. Trichome Financial's experienced founders and management team has a unique edge to capitalize on proprietary deal flow and industry insight while developing a first mover advantage as a global cannabis focused specialty finance company. Trichome Financial provides customized financing solutions across the industry value chain to support growth, capital expenditures, mergers, acquisitions, working capital and other needs. Leveraging the combined resources and knowledge of its founders, it is able to offer significant value-added financial, product, market and operational support to its partner companies.

For further information about Trichome Financial please visit us at www.trichomefinancial.com or @trichomefinance on Twitter and refer to the Company's SEDAR profile at www.sedar.com.

READER ADVISORY

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this press release.

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things: the Company's 2021 an run rate capacity flower production, revenue and EBITDA estimates, trends in Canadian recreational cannabis sales and future cash requirements by JWC, estimated cost savings following the restructuring of the JWC business, the commercial launch of JWC products based on new genetics and the timing thereof, and JWC sales and marketing initiatives. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; and the delay or failure to receive board, shareholder or regulatory approvals. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, Trichome Financial assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to United States Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Contact Information

Michael Ruscetta, CEO
Telephone: (416) 467-5229
info@trichomefinancial.com

Marc Charbin, Investor Relations
Telephone: (416) 467-5229
Email: marc.charbin@loderockadvisors.com

SOURCE: Trichome Financial Corp

ReleaseID: 603984

COEUR D'ALENE, ID / ACCESSWIRE / August 31, 2020 / New Jersey Mining Company (OTCQB:NJMC) ("NJMC" or the "Company") is pleased to announce it has closed a $2.7 million private placement from 18 investors and has also been notified of warrants to be exercised in connection with a private placement completed in October of 2017. The Company will receive an additional $258,000 upon exercise of the warrants.

Proceeds from the private placement will be used to accelerate a drill program targeting down-dip gold resource expansion and necessary underground mine development to facilitate the goal of doubling production over the next 12-18 months at the Company's Golden Chest mine in Idaho.

Proceeds from the warrant exercise from H&H Metals Corp. ($208,000), the Company's concentrate broker, and Company CEO and President John Swallow ($50,000), will be focused toward a phase 1 program (including a 10-hole core drill plan) aimed at the delineation of mineable resources at the Company's Diamond Hill and/or Roberts projects near Salmon, Idaho.

NJMC CEO and President John Swallow stated, "The Company was built on the reality that most of the storied world-class gold and silver mines began as smaller operations within notable mining districts. In our view, we have proven that becoming a modest producer and building on success is considerably more desirable than the risk of ‘starting big' and not being in production – and now growing into a larger producer – as gold approaches $2,000/ounce. NJMC has been purposely positioned to benefit from the momentum of higher gold prices (regardless of the reason). And together with the addition of two nationally recognized Rare Earth Element properties, the stage is now set for the pivot into becoming a much larger gold producer while advancing the ‘step and repeat' goal of defining a mineable Rare Earth Element resource base in Idaho.

As part of ongoing development and corporate growth, we look toward an exchange listing consistent with a higher level of production and sophisticated operations. Furthermore, we have a battle-tested team that welcomes the challenges of growth and team-building as we scale our culture and proven approach while simultaneously becoming a larger contributor to our state and local economies."

Highlights for 2020/2021 Exploration, Drilling and Development Programs:

Golden Chest

Drill Plan – 11,000 meters of core drilling. A resource definition drill plan designed to extend the underground resource at-depth on each of the six identified ore shoots. Only 29,000 meters have been drilled at the Golden Chest to date and were largely focused on open pit resource delineation so there is excellent potential to increase the mineable gold resource (and concurrent development) by targeting the vein system down-dip.

The deeper potential of the Golden Chest vein system is highlighted by drill hole GC12-112 which intercepted the Idaho vein in the Skookum Shoot area nearly 100 meters below the lowest current mining stope and assayed 6.79 grams per tonne (gpt) gold across a true thickness of 4.4 meters. The drill plan will target the vein below the GC 12-112 intercept with several holes spaced about 50 meters apart. Equally exciting is the drilling planned for the Klondike (below the upcoming Klondike open pit) and Katie-Dora shoots in the northern part of the mine where most of the historic mining occurred, but modern exploration drilling has been limited.

Underground Mine Capital Investment – Proceeds will also be used to develop the next lowest sublevel on the Skookum Shoot so the underground mining rate in just the Skookum can be increased to an additional 10,000 tonnes per year of ore. Using the average grade of mining in this area to date, that implies an increase of 2,000 ounces and sets the stage for a doubling of production. Another drill jumbo and LHD will be acquired and a full-time development crew has been added to the mine roster.

Murray Gold Belt (MGB)

Exploration – At the Buckskin, Evans and Big Ledge we are conducting a detailed mapping and sampling program designed to identify favorable target areas for second-phase trenching and drill programs. Based on the almost proprietary knowledge gained from past MGB exploration and operational and developmental experience at the Golden Chest, this is a logical next step toward locating more deposits in the MGB district. We believe there may be a buried alkaline intrusion in this area based on gold-bearing dikes with associated telluride mineralization – typical of areas with promising gold potential.

Diamond Creek – Rare Earth Elements (REE's)

As part of our three-phase plan to develop a reliable/mineable resource at Diamond Creek, phase 1 includes a detailed mapping and sampling program ahead of determining drill targets. A 10-hole core drilling program has already been developed for the Diamond Creek project, with the purpose of expanding and further clarify the REE resource outlined by the USGS in 1979. Drilling will target the Diamond Creek Fault as well as the associated REE vein occurrences. The phase 1 drill plan is being prepared for BLM review.

The private placement, which closed on August 28, 2020, consisted of units at a price of $0.28 per unit for a gross proceed of $2,737,000. Each Unit consists of one (1) share of the Company's restricted Common Stock and one-half (1/2) of one share Common Stock purchase warrant. Each whole warrant will be exercisable by the holder into shares of the Company's restricted Common Stock at $0.40 per share for 24-months commencing at the closing of the offering. The exercise of 1,2291,667 warrants in connection with the October 2017 private placement will be exercised at $0.20 per share for net proceeds of $258,333.00.

Qualified person

NJMC's Vice President, Grant A. Brackebusch, P.E. is a qualified person as such term is defined in National Instrument 43-101 and has reviewed and approved the technical information and data included in this press release.

About New Jersey Mining Company

Headquartered in North Idaho, New Jersey Mining Company is the rare example of a vertically integrated, operating junior mining company. NJMC produces gold at the Golden Chest Mine and recently consolidated the Murray Gold Belt (MGB) for the first time in over 100-years. The MGB is an overlooked gold producing region within the Coeur d'Alene Mining District, located north of the prolific Silver Valley. In addition to gold, the Company maintains a presence in the Critical Minerals sector and is focused on identifying and exploring for Critical Minerals (Rare Earth Minerals) important to our country's defensive readiness and a low-carbon future.

New Jersey Mining Company possesses the in-house skillsets of a much larger company while enjoying the flexibility of a smaller and more entrepreneurial corporate structure. Its production-based strategy, by design, provides the flexibility to advance the Murray Gold Belt and/or its Critical Minerals holdings on its own or with a strategic partner in a manner that is consistent with its existing philosophy and culture.

NJMC has established a high-quality, early to advanced-stage asset base in four historic mining districts of Idaho and Montana, which includes the currently producing Golden Chest Mine. Management is stakeholder focused and owns more than 15-percent of NJMC stock.

The Company's common stock trades on the OTC-QB under the symbol "NJMC."

For more information on New Jersey Mining Company go to www.newjerseymining.com or call:

Monique Hayes, Corporate Secretary/Investor Relations
Email: monique@newjerseymining.com
(208) 625-9001

Forward Looking Statements

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that are intended to be covered by the safe harbor created by such sections. Such statements are based on good faith assumptions that New Jersey Mining Company believes are reasonable, but which are subject to a wide range of uncertainties and business risks that could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Such factors include, among others, the, the risk that exploration and development will result in increased production, the mine plan changes due to rising costs or other operational details, an increased risk associated with production activities occurring without completion of a feasibility study of mineral reserves demonstrating economic and technical viability, the risks and hazards inherent in the mining business (including risks inherent in developing mining projects, environmental hazards, industrial accidents, weather or geologically related conditions), changes in the market prices of gold and silver and the potential impact on revenues from changes in the market price of gold and cash costs, a sustained lower price environment, as well as other uncertainties and risk factors. Actual results, developments and timetables could vary significantly from the estimates presented. Readers are cautioned not to put undue reliance on forward-looking statements. NJMC disclaims any intent or obligation to update publicly such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: New Jersey Mining Company

ReleaseID: 604008

Minimum Investment of $250

WESTMORELAND, JAMAICA / ACCESSWIRE / August 31, 2020 / Virtudes Labs, Inc. slated to be the first vertically-integrated hemp producer and processor of high-grade CBD oil from Jamaica farms announced today that it can now accept online investments from non-accredited or ordinary investors on the Fundanna platform here: https://fundanna.com/equity/offer-summary/VirtudesLabs. Industry companies and accredited investors who wish to inquirer regarding strategic partnerships, joint ventures, or investing in Virtudes can contact Farrah Zargaran, COO directly at (972) 806 – 2688 or farrah@virtudescompany.com.

About Virtudes

Virtudes is slated to be the first vertically integrated hemp producer and processor of high-grade CBD oil from Jamaican farms. Owned by American shareholders, Virtudes is incorporated and registered in Jamaica. The Company recently acquired over 100 acres of land in Jamaica and is expected to have its first hemp crop during 2020.

Hemp grown in lush Jamaican climate is the foundation for an organic and natural product that we audaciously aim to provide to the world. From seed to sale, we pledge to produce top-quality cannabis outputs in Jamaican farms with the integration of traditional and modern cultivation styles. The year-round sunshine and steady rainfall create an ideal environment for flowers to produce industry-leading, outdoor-grown medical cannabis.

As a global company, Virtudes is navigating a movement towards establishing credibility and value to one of the world's more useful plants. With strong medicinal benefits, Cannabis-sativa (commonly known as hemp), is breaking down boundaries within every international industry.

At the intersection of experienced farming practices and centuries of cannabis cultivation knowledge, Virtudes is prepared to provide a high-end cannabis product that will also bring value back into its community. Virtudes is fully dedicated to being involved in the extensive research and development of the benefits and advancements of cannabis plants and their byproducts for both daily and medicinal health.

Legal Disclaimer

Virtudes and www.virtudescompany.com are operated by Virtudes Labs, Inc., investment opportunities in the Reg CF offering are not a public offering, are private placements, are subject to long hold periods, are illiquid investments and investors must be able to afford the loss of their entire principal. There is no guarantee that Virtudes will register its shares with the SEC or any stock exchange. Offers to buy or sell any security can only be made through official offering and subscription documents that contain important information about risks, fees, and expenses. You should conduct your own due diligence including reviewing in detail the Offering Circular and consultation with a financial advisor, attorney, accountant, or other professional that can help you to understand the risks associated with the investment opportunity.

Forward-Looking Statements

This release may contain forward-looking statements regarding Virtude's projected business performance, operating results, financial condition, and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." These statements also include estimates of the pace of customer adoption of the company's products, engineering developments and prototype capabilities. Please be advised that such statements are intentions or estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company, or that the company will be able to consummate its planned goals (including without limitation, a public listing of its securities). Forward-looking statements may be based on management assumptions that prove to be wrong. The Company's predictions may not be realized for a variety of reasons, including due to inability to raise a sufficient amount of funds, a lack of marketability for the company's securities, failure of business operations, competition, customer sales cycles, and engineering or technical issues, among others. The Company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

Contact:

Virtudes Labs, Inc.
Farrah Zargaran, COO
(972) 806 – 2688
farrah@virtudescompany.com
www.virtudescompany.com

SOURCE: Cannabis Investor Magazine

ReleaseID: 604026

RALEIGH, NC / ACCESSWIRE / August 31, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the formation of its scientific advisory board (SAB). The SAB comprises an esteemed group of six experts in the gastroenterology field with sub-specialties in celiac disease, inflammatory bowel disease (IBD) and functional GI diseases. They will work closely with the 9 Meters leadership team in advancing the clinical development of the company's co-lead assets, NM-002 for the treatment of short bowel syndrome (SBS) and larazotide for the treatment of celiac disease.

"Having access to the knowledge and expertise of these six individuals on our SAB will be incredibly valuable as we advance our candidates for both celiac disease and SBS," said John Temperato, president and chief executive officer of 9 Meters. "We feel privileged to have the opportunity to bring this board's understanding of gastrointestinal disorders and experience in clinical research to our own drug development process and look forward to their contributions, especially as we complete the first Phase 3 trial ever conducted for the treatment of celiac disease."

The SAB will comprise the following members:

Mark Pimentel, M.D., Cedars Sinai Medical Center

Mark Pimentel, M.D., is currently the head of the Pimentel Laboratory and executive director of the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai. The program is focused on the development of drugs, diagnostic tests and devices related to conditions of the microbiome. His research interests include IBD and functional GI diseases, and his lab has discovered a blood test to provide a definitive diagnosis for IBS for the first time. He received his M.D. from University of Manitoba. For more information on Dr. Pimentel, please visit: https://ceda.rs/33QqCMo.

Z. Myron Falchuk, M.D., Beth Israel Deaconess Medical Center

Z. Myron Falchuk, M.D., is an Associate Clinical Professor of Medicine at Harvard Medical School and previously was a practicing physician at Beth Israel Deaconess Medical Center (BIDMC) for Endoscopy and the Division of Gastroenterology/GI. His clinical interests include general gastroenterology, inflammatory bowel disease, cancer of the colon, celiac disease, colonoscopy and gastroscopy. He received his medical degree from Harvard Medical School. For more information on Dr. Falchuk, please visit: https://bit.ly/3gSPdny

Charles Randall, M.D., Gastroenterology Research of America; UT San Antonio Medical Center

Charles Randall, M.D., is a Clinical Professor of Medicine at the University of Texas Health Science Center, as well as the CEO and founder of Gastroenterology Research of America, where he works with the pharmaceutical industry to develop new products and leads the board in expansion and growth of the company as the leader in GI clinical research in America. His research interests include IBD, IBS, esophageal disorders, dysmotility syndromes and novel endoscopic techniques. He received his medical degree from the University of Texas Medical Branch. For more information on Dr. Randall, please visit: https://bit.ly/3gQkG9T

Benjamin Lebwohl, M.D., M.S., Columbia University Irving Medical Center

Benjamin Lebwohl, M.D., M.S., has been a faculty member of the Celiac Disease Center at Columbia University since 2010, where he is collaborating with institutions in the United States and abroad in the areas of the epidemiology, patterns of care and the natural history of celiac disease. He also currently serves as a member of the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) and is an Associate Professor of Medicine and Epidemiology at the Columbia University Irving Medical Center. He received his M.D. from Columbia College of Physicians and Surgeons. For more information on Dr. Lebwohl, please visit: https://bit.ly/3iu1fEj

Russel Cohen, M.D., University of Chicago

Russel Cohen, M.D., is a Professor of Medicine, Director of the Inflammatory Bowel Disease Center and Co-Director of the Advanced IBD Fellowship Program at University of Chicago Medicine. He has clinical expertise in inflammatory bowel disease (IBD) and has been actively involved in several long-term research studies testing oral and intravenous drugs in patients with IBD. He received his M.D. from Mount Sinai School of Medicine. For more information on Dr. Cohen, please visit: https://bit.ly/2CmiW9u

Maureen Leonard, M.D., Harvard Medical School

Maureen Leonard, M.D., is the Clinical Director at the Center for Celiac Research and Treatment at Massachusetts General Hospital for Children (MGHfC) and an Assistant Professor of Pediatrics at Harvard Medical School. Several of her clinical interests include celiac disease, non-celiac gluten sensitivity, non-responsive celiac disease, refractory celiac disease and gluten-related disorders. She received her medical degree from New York Medical College. For more information on Dr. Leonard, please visit: https://bit.ly/3kulvYl

About 9 Meters Biopharma

9 Meters Biopharma, Inc. ("the Company") is a rare and unmet needs-focused gastroenterology company. The Company is advancing NM-002, a proprietary long-acting GLP-1 agonist into a Phase 2 trial for Short Bowel Syndrome (SBS), a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease.

For more information, please visit www.9meters.com or follow 9 Meters on Twitter and LinkedIn.

Forward-looking Statements

This press release includes forward-looking statements based upon the Company's current expectations. Forward-looking statements involve risks and uncertainties, and include, but are not limited to, the potential effects of the ongoing coronavirus outbreak and related mitigation efforts on the Company's clinical, financial and operational activities; the Company's continued listing on Nasdaq; expectations regarding future financings; the future operations of the Company; the nature, strategy and focus of the Company; the development and commercial potential and potential benefits of any product candidates of the Company; anticipated preclinical and clinical drug development activities and related timelines, including the expected timing for data and other clinical and preclinical results; the Company having sufficient resources to advance its pipeline; and any other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: (i) uncertainties associated with the clinical development and regulatory approval of product candidates; (ii) risks related to the inability of the Company to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs; (iii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (iv) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (v) the impact of COVID-19 on our operations, clinical trials or proposed merger and future financings and (vi) risks associated with the possible failure to realize certain anticipated benefits of the Company's recent merger and the Naia acquisition, including with respect to future financial and operating results. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements because of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in the Company's. Annual Report on Form 10-K for the year ended December 31, 2019, Form 10-Q for the quarter ended June 30, 2020 and in other filings that the Company has made and future filings the Company will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. The company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Corporate contacts

Edward J. Sitar
Chief Financial Officer
9 Meters Biopharma, Inc.
investor-relations@9meters.com
www.9meters.com

Media contact

Amy Jobe, Ph.D.
LifeSci Communications, LLC
ajobe@lifescicomms.com
315-879-8192

Investor contact

Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577

SOURCE: 9 Meters Biopharma

ReleaseID: 603785

Conference Call Scheduled for 4:30pm ET

EDGEWATER, NJ / ACCESSWIRE / August 31, 2020 / Quad M Solutions, Inc. (OTC PINK:MMMM) ("Quad M" or the "Company"), a public holding company that offers staffing services and employee benefits such as health plans, HR-human resources, and payroll services, to small and mid-sized group employers, today announced that it will host a conference call to discuss its proposed (under Definitive Agreement) acquisition of iCan Benefits Group on Tuesday, September 1, 2020 at 4:30pm ET. The details for the conference call can be found below.

If you have a question you would like addressed on the call, please submit it to IR@QuadMSolutions.com. The Company do its best to answer all submitted questions after its prepared remarks.

Quad M Solutions Acquisition of iCan Benefits Group Conference Call
Date: Tuesday, September 1, 2020
Time: 4:30 PM ET
Dial-in: 1-877-407-0778 (Domestic)
1-201-689-8565 (International)
Webcast: https://www.webcaster4.com/Webcast/Page/2496/37142
Replay: 1-877-481-4010 (Domestic)
1-919-882-2331 (International)
Replay Passcode: 37142

About Quad M Solutions, Inc.

Quad M Solutions, Inc., is a public holding company that offers self-funded health plans, staffing services, HR-human resources, payroll services, retirement, supplemental and workers compensation insurance to small and mid-sized group employers with 1-500 employees, and to the exploding essential worker "Gig Economy," a labor market that is characterized by the prevalence of short-term contracts or freelance work, not permanent jobs. The company's four subsidiaries, NuAxess 2, Inc., PrimeAxess, Inc., OpenAxess, Inc. and PrimeAxess 2, LLC are important in conveying who we are and what we do.

We strive to provide those employers and individuals the right tools to be able to manage and control all the facets in their healthcare experience and their eventual health outcomes. Prevention, wellness, and cures have become part of our corporate mission to individuals who want to manage and control their short and long-term healthcare needs.

Our self-insured programs are consumer-driven and technology-leveraged and, by itself, self-insurance is affordable, transparent and responsive to the healthcare and retirement needs of employees who are looking for higher quality benefits, integrated health information and better medical provider access and outcomes.

For additional information, please visit: QuadMSolutions.com and NuAxess.com.

Forward-looking Statements:

The statements contained herein that are not historical facts are forward-looking statements within the meaning of the federal securities laws (Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). You can identify such forward-looking statements by the words "expects," "intends," "plans," "projects," "believes," "estimates," "likely," "possibly," "probably," "goal," "opportunity," "objective," "target," "assume," "outlook," "guidance," "predicts," "appears," "indicator" and similar expressions. Forward-looking statements involve a number of risks and uncertainties. In the normal course of business, Quad M Solutions, in an effort to help keep our stockholders and the public informed about our operations, may from time to time issue such forward-looking statements, either orally or in writing. Generally, these statements relate to business plans or strategies, projected or anticipated benefits or other consequences of such plans or strategies, or projections involving anticipated revenues, earnings, profits, pricing, operating expenses or other aspects of operating results. We base the forward-looking statements on our expectations, estimates, and projections at the time such statements are made. These statements are not guarantees of future performance and involve risks and uncertainties that we cannot predict. In addition, we have based many of these forward-looking statements on assumptions about future events that may prove to be inaccurate. The actual results of the future events described in such forward-looking statements could differ materially from those stated in such forward-looking statements.

Corporate Contact:

Pat Dileo
CEO, Chairman, Quad M Solutions, Inc.
p732-423-5520
p844-NuAxess

Investors:
IR@QuadMsolutions.com

SOURCE: Quad M Solutions, Inc.

ReleaseID: 603944